Localization of the Gene for the Intermediate Form of Charcot-Marie-Tooth to Chromosome 10q24.1-q25.1  by Verhoeven, Kristien et al.
Am. J. Hum. Genet. 69:889–894, 2001
889
Report
Localization of the Gene for the Intermediate Form
of Charcot-Marie-Tooth to Chromosome 10q24.1-q25.1
Kristien Verhoeven,1 Marcello Villanova,3 Alessandro Rossi,4 Alessandro Malandrini,4
Peter De Jonghe,1,2 and Vincent Timmerman1
1Department of Molecular Genetics, Flanders Interuniversity Institute for Biotechnology, Born-Bunge Foundation, University of Antwerp, and
2Division of Neurology, University Hospital Antwerp, Antwerpen; 3Istituto Ortopedico Rizzoli, Bologna; and 4The Institute of Neurological
Sciences, University of Siena, Siena, Italy
Intermediate Charcot-Marie-Tooth neuropathy (CMT) is an inherited sensory motor neuropathy characterized by
motor median nerve conduction velocities of 25–45 m/s. We performed a genomewide search in an Italian family
with autosomal dominant intermediate CMT and mapped the locus on chromosome 10q. Analysis of key recom-
binants maps the gene for autosomal dominant intermediate CMT to a 10.7-Mb interval on chromosome 10q24.1-
q25.1, between simple tandem repeat markers D10S1709 and D10S1795.
Charcot-Marie-Tooth (CMT) disease is a clinically and
genetically heterogeneous disorder of the peripheral
nervous system, characterized by progressive weakness
and atrophy, initially of the peroneal muscles and later
of the distal muscles of the arms. CMT neuropathy is
subdivided into CMT1 and CMT2 on the basis of elec-
trophysiological and neuropathological criteria (Dyck et
al. 1993). CMT1 or hereditary motor and sensory neu-
ropathy type I (HMSN I) is a demyelinating neuropathy,
whereas CMT2 (or HMSN II) is an axonal neuropathy.
Most patients with CMT can be classified as having
either CMT1 or CMT2 by use of a cut-off value of 38
m/s for the motor median nerve-conduction velocity
(NCV). However, in some families with CMT, patients
have motor median NCVs ranging from 25 to 45 m/s.
It has been proposed to designate this form as “inter-
mediate CMT” (Davis et al. 1978).
Genetic-linkage studies have demonstrated that
CMT1 and CMT2 are extremely genetically heteroge-
neous. The majority of CMT1 patients have a 1.4-Mb
tandem duplication in chromosome 17p12 (CMT1A
[MIM 118220]) harboring the peripheral myelin protein
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22 (PMP22 [MIM 601097]) gene (Lupski et al. 1991;
Raeymaekers et al. 1991; Inoue et al. 2001). Further-
more, disease-causing mutations in at least nine genes
have been identified for CMT neuropathy and related
HMSN disorders: PMP22 in CMT1A (Valentijn et al.
1992), myelin protein zero (MPZ/P0 [MIM 159440]) in
CMT1B (MIM 118200; Hayasaka et al. 1993), early
growth response element 2 (EGR2 [MIM 129010]) in
CMT1 (Warner et al. 1998); connexin 32 (Cx32/GJB1
[MIM 304040]) in CMT1X (MIM 304040; Bergoffen
et al. 1993); myotubularin related protein 2 (MTMR2
[MIM 603557]) in CMT4B (MIM 601382; Bolino et al.
2000), N-myc downstream regulated gene 1 (NDRG1
[MIM 605262]) in HMSN-LOM (MIM 601455; Ka-
laydjieva et al. 2000), periaxin (PRX [MIM 605725])
in CMT4F (MIM 145900; Boerkoel et al. 2001), kinesin
family member 1B (KIF1B [MIM 605995]) in CMT2A
(MIM 118210; Zhao et al. 2001); and neurofilament
light chain (NEFL [MIM 162280]) in CMT2E (MIM
162280; Mersiyanova et al. 2000). The mutations and
the corresponding phenotypes are summarized in the
Inherited Peripheral Neuropathy Mutation Database.
Also, other loci harboring currently unknown gene
defects have been identified for CMT1 and CMT2 (De
Jonghe et al. 2000). So far, autosomal dominant inter-
mediate CMT has not been mapped in the human ge-
nome. Interestingly, in some affected families with very
variable NCVs ranging from normal to severely reduced,
specific mutations in theMPZ gene have been described
(De Jonghe et al. 1999). A similar phenotype is associ-
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Figure 1 Linkage pedigree of the Italian family with autosomal dominant intermediate CMT (Rossi et al. 1985), showing the most likely
haplotypes for the chromosome 10q markers. The haplotype segregating with the disease is boxed. Blackened symbols represent affected
individuals, unblackened symbols represent unaffected individuals, and half-blackened symbols represent individuals with unknown disease
status. Arrows indicate recombinants.
ated with mutations in NEFL (De Jonghe et al. 2001).
Interestingly, mutations in the Cx32 gene causing
CMT1X lead to an intermediate type of CMT in male
patients, whereas female mutation carriers often have
normal NCVs (Nicholson and Nash 1993; Timmerman
et al. 1996; Birouk et al. 1998).
We previously studied a large Italian family diagnosed
with autosomal dominant intermediate CMT. Detailed
clinical and neurophysiological studies of this family
have been reported (Rossi et al. 1985; Villanova et al.
1998). In brief, this type of CMT is clinically charac-
terized by difficulties in walking on the heels from age
6 years. In the second decade of life, patients experience
weakness in the lower limbs, with difficulties in running.
From 25 to 30 years of age, the disease progresses slowly
but steadily. From 40 to 50 years, the disease progresses
very rapidly, and patients develop severe weakness and
atrophy of distal leg and intrinsic handmuscles, steppage
gait, and pes cavus. Later in life, the disease seems to
stabilize. After age 70 years, crutches are needed towalk.
However, none of our patients is wheelchair bound.
Neurophysiological studies performed on 10 affected
family members, with ages ranging from 11 to 72 years,
showmotor median NCVs between 25 and 45m/s. NCV
slowing is proportionate to the severity of the clinical
deficits. A peripheral nerve biopsy shows the simulta-
neous presence of demyelinating features, such as onion-
bulb formations and uncompacted enlarged myelin la-
mellae, and signs of chronic axonal degeneration with
regeneration, such as large fiber loss and regeneration
clusters (Malandrini et al., in press).
In this Italian family with autosomal dominant inter-
mediate CMT, we previously excluded the CMT1A
tandem duplication on chromosome 17p12, and no
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Table 1
Two-Point LOD Scores between the Intermediate CMT Locus and
Chromosome 10q Markers
MARKER
LOD AT v p
.00 .001 .01 .05 .10 .20 .30 .40
D10S1758 1.94 4.83 5.77 5.94 5.56 4.39 2.97 1.42
D10S1709 .60 2.33 3.23 3.46 3.16 2.21 1.17 .36
D10S1726 1.05 2.83 3.76 4.13 3.97 3.21 2.17 1.01
D10S1710 2.32 .35 .59 1.11 1.18 1.01 .72 .37
D10S192 .28 2.21 3.15 3.57 3.46 2.80 1.88 .86
D10S1692 4.20 4.19 4.11 3.77 3.33 2.42 1.49 .62
D10S205 1.65 3.59 4.51 4.83 4.60 3.68 2.47 1.13
D10S1268 1.89 3.83 4.74 5.05 4.80 3.84 2.57 1.18
D10S540 1.24 .72 1.65 2.08 2.03 1.60 1.03 .44
D10S1795 4.46 .68 1.21 2.20 2.27 1.72 .92 .27
D10S1750 5.54 2.22 .27 .93 1.25 1.20 .84 .40
mutations were found in the peripheral myelin genes
PMP22 and MPZ. Furthermore, we performed genetic
linkage studies and excluded all known CMT1 and
CMT2 loci (Villanova et al. 1998). Here, we report the
results of a genomewide scan.
The family contains a total of 38 individuals, 20 of
whom are affected (fig. 1). Genomic DNA of all 38 fam-
ily members was isolated and purified from peripheral
blood samples using standard techniques. The study was
approved by the institutional review boards at the Uni-
versities of Siena and Bologna (Italy) and Antwerp (Bel-
gium), and informed consent was obtained from all fam-
ily members. A genomewide scan was performed using
all 400 markers of the ABI Prism Linkage Mapping Set
MD-10 (PE Biosystems), which have an average inter-
marker distance of 10 cM. PCR products were amplified
on an MJ Research PTC 200 thermocycler, were pooled
using a Beckman Biomek 2000 workstation, and were
loaded on an ABI 3700 automated sequencer (PE Bio-
systems). Data were analyzed by means of ABI Genescan
3.1 and ABI Genotyper 2.1 software. Linkage analysis
was carried out using the Linkage 5.1 program package
and the Fastlink computer program (Lathrop and La-
louel 1984; Cottingham et al. 1993). Mlink two-point
linkage analysis was performed between the disease gene
and each simple tandem repeat (STR) marker. Inter-
mediate CMT was coded as a 90% penetrant autosomal
dominant trait with a gene frequency of .0001. Equal
recombination rates between males and females were
assumed. For each STR marker, the number of alleles in
the LOD score calculations was set at the observed num-
ber of alleles in the pedigree (N), and the allele fre-
quencies were set at 1/N.No markers of the ABI linkage
panel gave LOD scores 12.5, except for marker
D10S192, localized on the long arm of chromosome 10.
With this STR marker, a significant LOD score of 3.15
at was obtained (table 1). Therefore, additionalvp .01
markers spanning this region were selected from the Ge-
nome Database (fig. 2). The two-point LOD scores ob-
tained with these markers are shown in table 1. Several
markers gave LOD scores 14.
The most likely disease haplotype was constructed
(fig. 1). In all affected family members, a linked haplo-
type was found. Two key recombinants were identified.
In patient IV-16, a recombination was present between
markers D10S540 and D10S1795, placing the inter-
mediate CMT gene centromeric of marker D10S1795.
Another recombination event occurred in patient V-2,
between markers D10S1709 andD10S1726. Combining
the information of these two recombinants places the
intermediate CMT gene in a 10.7-Mb region (Human
Genome Browser) between markers D10S1709 and
D10S1795. Finally, to find other chromosome 10q24.1-
25.1 linked families, we performed a genetic linkage
study in four large families compatible with intermediate
CMT or CMT2 and were able to exclude the chromo-
some 10q locus in these families (data not shown).
The 10.7-Mb critical region has been almost completely
sequenced, and 170 genes have been mapped (Human
Genome Browser) between D10S1709 and D10S1795.
Therefore, a refinement of the candidate region will be
required before a systematic mutation screening of the
genes located in the region can be undertaken. As a start,
we selected the internexin neuronal intermediate filament
protein alpha (INA [MIM 605338]) gene (GenBank ac-
cession number NM_032727) as the most obvious func-
tional candidate gene for intermediate CMT. Alpha-in-
ternexin is a type IV intermediate filament protein that is
expressed abundantly in neurons during development of
the peripheral and central nervous system. It has been
suggested that alpha-internexin may play a role in sta-
bilizing small-diameter axons and may act as a scaffold
on which the neurofilament-light, -medium (NEFM
[MIM 162250]), and -high (NEFH [MIM 162230]) pro-
teins coassemble during development (Ching et al. 1999;
Julien 1999). Unexpectedly, overexpression of (as well
as the absence of) alpha-internexin does not seem to
interfere with normal axonal growth (Levavasseur et al.
1999). As the effects of missense and nonsensemutations
in alpha-internexin have not been investigated, and mu-
tations in the NEFL gene have been shown to cause
CMT type 2E (CMT2E), alpha-internexin still seemed
to be a good candidate gene for intermediate CMT.
However, mutation analysis of the coding sequence of
the alpha-internexin gene did not reveal any disease-
causing mutations (data not shown). Since chromosome
10q has many genes associated with neuronal function,
other possible candidate genes are under investigation
for mutation analysis, such as ACTR1A (actin-related
protein 1 [MIM 605143]) andNEURL (neuralizedDro-
sophila-like [MIM 603804]).
The autosomal dominant intermediate CMT in this
Italian family is the third locus for an inherited periph-
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Figure 2 Genetic map of the chromosome 10q region containing
the intermediate CMT locus (Human Genome Browser). Physical dis-
tances between the markers are given in megabases. The intermediate
CMT region is indicated by the thick black line. The INA gene is
located between markers D10S1692 and D10S205.
eral neuropathy that has been located on the long arm
of chromosome 10. Previously, the EGR2 gene, a tran-
scription factor with a key role in peripheral nerve my-
elination, was located on 10q21.1-q22.1 (Warner et al.
1998). Mutations in the EGR2 gene have been shown
to cause congenital hypomyelinating neuropathy (CHN
[MIM 605253]), CMT1, and Dejerine-Sottas Syndrome
(DSS [MIM 145900]) (Warner et al. 1998; Timmerman
et al. 1999). Recently, a novel locus for a recessively
inherited form of CMT, named “hereditary motor and
sensory neuropathy–Russe” (HMSN-R [MIM605285]),
was located on 10q23.2. It is a severe disabling form of
CMT with prominent sensory loss, moderately reduced
motor NCV, and a high threshold for electrical nerve
stimulation (Rogers et al. 2000). However, exclusion of
the intermediate-CMT locus from both regions is sup-
ported by the physical map of the region which places
the HMSN-R locus  30 cM centromeric of the prox-
imal boundary of the intermediate-CMT locus.
The term “intermediate CMT” was initially proposed
by Davis et al. (1978) but never gained general accep-
tance. They distinguished three types of CMT: a hyper-
trophic form with motor median NCVs !25 m/s, an
intermediate form with NCVs ranging from 25 to 45
m/s, and a neuronal form with NCVs 145 m/s. Inter-
mediate NCVs are often observed in X-linked CMT1
with Cx32 mutations (Nicholson and Nash 1993; Tim-
merman et al. 1996; Birouk et al. 1998). Presumably,
the intermediate group of Davis et al. (1978) included
mainly male patients with CMT1X, since the male:fe-
male ratio in this group was almost 2:1. The existence
of an X-linked form of CMT1, however, was not gen-
erally accepted at that time (Harding and Thomas 1980).
Furthermore, intermediate NCVs are also found in
patients with a specific mutation in the MPZ gene
(Thr124Met) or the NEFL gene (Pro8Arg) (De Jonghe
et al. 1999, 2001). Our Italian family with CMT and
intermediate NCVs is, however, clearly autosomal dom-
inant, and no mutations were found in the MPZ and
NEFL genes.
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